Another in vivo CRISPR screen in a PDA mouse model identified that KDM3A potentially blocks T cell-mediated immune response via regulating the expression of epidermal growth factor receptor (EGFR) through the Krueppel-like factor 5 (KLF5) and SMAD family member 4 (SMAD4) (102), which makes KDM3A a potential target for cancer therapy. This evidence concerns the gene KDM3A and Patent ductus arteriosus.